Drug Trial Radar · NCT00080301
Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer
Last checked: Nov 20, 2026Latest source record: Nov 2, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
752
Actual
Start
Sep 2003
Primary completion
Nov 2006
Study completion Mar 2008
Sponsor
- Lead sponsor
- R-PharmIndustry
- Sponsor type
- Industry
- First posted
- Mar 30, 2004
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical research study is to learn if BMS-247550 added to the approved therapy of capecitabine is better than capecitabine alone in shrinking or slowing the growth of the cancer in women with metastatic breast cancer who are resistant to taxane and received anthracycline chemotherapy. The safety of this treatment will also be studied.
Conditions
- Breast Cancer
- Metastases
Interventions
Ixabepilone + CapecitabineDrug
Ixabepilone - Intravenous Solution, IV 40mg/m², Day 1 every 21 days, Until progression/unacceptable toxicity Capecitabine (Active Comparator) - Tablet, Oral, 2000 mg/m², Bid Days 1-14 every 21 days, Until progression/unacceptable toxicity
CapecitabineDrug
Tablet, Oral, 2500 mg/m², Bid Days 1-14 every 21 days, Until progression/unacceptable toxicity
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS) Per Independent Radiology Review Committee (IRRC)Time frame: based on assessments every 6 weeks while on treatment until documented disease progression/unacceptable toxicity
Locations
127 sites in 22 countries. Site status is shown where the registry gives one.
Local Institution
Little Rock, Arkansas
Local Institution
San Francisco, California
Local Institution
Vallejo, California
Local Institution
Denver, Colorado
Local Institution
Hartford, Connecticut
Local Institution
Washington D.C., District of Columbia
Local Institution
Orlando, Florida
Local Institution
Baltimore, Maryland
Local Institution
Burlington, Massachusetts
Local Institution
Jackson, Mississippi
Local Institution
Columbia, Missouri
Local Institution
Kansas City, Missouri
Local Institution
St Louis, Missouri
Local Institution
Omaha, Nebraska
Local Institution
Livingston, New Jersey
Local Institution
New Brunswick, New Jersey
Local Institution
Albuquerque, New Mexico
Local Institution
New York, New York
Local Institution
Columbus, Ohio
Local Institution
Oklahoma City, Oklahoma
Local Institution
Tulsa, Oklahoma
Local Institution
Pittsburgh, Pennsylvania
Local Institution
Columbia, South Carolina
Local Institution
Greenville, South Carolina
Local Institution
Knoxville, Tennessee
Local Institution
Nashville, Tennessee
Local Institution
Austin, Texas
Local Institution
Houston, Texas
Local Institution
Ogden, Utah
Local Institution
Burlington, Vermont
Local Institution
Tacoma, Washington
Local Institution
Morgantown, West Virginia
Local Institution
Córdoba, Argentina
Local Institution
Neuquén, Argentina
Local Institution
Santa Fe, Argentina
Local Institution
Capital Federal, Buenos Aires, Argentina
Local Institution
Haedo, Buenos Aires, Argentina
Local Institution
La Plata, Buenos Aires, Argentina
Local Institution
Mar del Plata, Buenos Aires, Argentina
Local Institution
Pilar, Buenos Aires, Argentina
Showing 40 of 127 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.